Genitourinary Cancer
From the Journals
Patient-reported outcomes highlight long-term impacts of prostatectomy
Patients with high-risk disease who underwent prostatectomy also reported worse sexual function at every time point over 5 years.
From the Journals
HRQoL deteriorates during chemoradiotherapy for bladder cancer
However, in an exploratory analysis of 452 patients, health-related quality of life improved to pretreatment levels within 6 months following...
News from the FDA/CDC
FDA approves pembrolizumab for BCG-unresponsive NMIBC with CIS
The checkpoint inhibitor is approved for patients who are ineligible for or have elected not to undergo cystectomy.
From the Journals
Study simplifies bladder cancer molecular subtypes
Investigators divided muscle-invasive bladder cancer into six molecular classes based on disease factors and those consensus classes predicted...
From the Journals
Urothelial cancer: Less gained from immunotherapy in patients with poor performance scores
Among patients given immune checkpoint inhibitors in the first-line setting, overall survival was more than twice as long for those with a good...
News
FDA approves antibody-drug conjugate for advanced urothelial cancer
Enfortumab vedotin-ejfv was granted accelerated approval based on an overall response rate of 44%.
From the Journals
RCC: Tivozanib beats sorafenib in later lines
In TIVO-3, a phase 3 trial involving 350 patients with metastatic RCC who had been treated with two or more systemic therapies, patients in the...
News
FDA expands Xtandi approval to mCSPC
Enzalutamide was previously approved for castration-resistant prostate cancer.
From the Journals
Single-fraction radiation just misses mark for spinal compression relief
The primary noninferiority endpoint was not met, but a small difference between single- and multi-fraction radiation may not be clinically...
From the Journals
Atezolizumab/bevacizumab may offer benefit to patients with RCC
The combination performed better in renal cell carcinoma patients who were PD-L1 positive.
Conference Coverage
Combo shows promise for checkpoint inhibitor-refractory urothelial carcinoma
NATIONAL HARBOR, MD – Combination sitravatinib and nivolumab produced responses in patients with checkpoint...